# Efficacy of Propranolol Treatment to Prevent Melanoma Progression

> **NCT01988831** · PHASE2 · SUSPENDED · sponsor: **University Hospital, Geneva** · enrollment: 450 (estimated)

## Conditions studied

- Stages III Skin Melanoma
- Stages II Skin Melanoma
- Stage IB Skin Melanoma

## Interventions

- **DRUG:** Propranolol hydrochloride
- **DRUG:** Placebo pill

## Key facts

- **NCT ID:** NCT01988831
- **Lead sponsor:** University Hospital, Geneva
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2016-06
- **Primary completion:** 2022-01
- **Final completion:** 2022-03
- **Target enrollment:** 450 (ESTIMATED)
- **Why stopped:** We must delay the study for some financial reasons
- **Last updated:** 2019-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01988831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01988831, "Efficacy of Propranolol Treatment to Prevent Melanoma Progression". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT01988831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*